Volatility & Risk
TransEnterix has a beta of 2.56, meaning that its share price is 156% more volatile than the S&P 500. Comparatively, Longevity Health has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.
Profitability
This table compares TransEnterix and Longevity Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TransEnterix | -2,149.15% | -83.74% | -64.94% |
| Longevity Health | -1,535.11% | N/A | -280.07% |
Valuation and Earnings
This table compares TransEnterix and Longevity Health”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TransEnterix | $8.53 million | 2.51 | -$154.20 million | ($4.22) | -0.04 |
| Longevity Health | $560,671.00 | 3.96 | -$10.37 million | N/A | N/A |
Longevity Health has lower revenue, but higher earnings than TransEnterix.
Institutional & Insider Ownership
8.2% of TransEnterix shares are owned by institutional investors. Comparatively, 24.2% of Longevity Health shares are owned by institutional investors. 3.1% of TransEnterix shares are owned by insiders. Comparatively, 29.0% of Longevity Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Longevity Health beats TransEnterix on 6 of the 9 factors compared between the two stocks.
About TransEnterix
TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.
About Longevity Health
Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.
Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.
